BD Acquisition of Bard


BD and Bard announced on April 23, 2017 that they have entered into a definitive agreement under which BD will acquire Bard for $317.00 per Bard common share in cash and stock, for a total consideration of $24 billion, creating a highly differentiated medical technology company focused on delivering innovative healthcare solutions to improve clinical and economic outcomes.